Dicerna Pharmaceuticals, Inc.

Subsidiary of Novo Nordisk (NVO)

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
LPA gene / apolipoprotein(a) mRNARNA / oligonucleotide
Atherosclerotic Cardiovascular Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (2)
March 2029 (1)
LepodisiranPhase 3Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Est. primary completion 2029-03 · NCT06292013 · CT.gov ↗
What to watch
December 2029 (1)
LepodisiranPhase 3Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Est. primary completion 2029-12 · NCT07613294 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.